GlassScriptPhysician profile
Robin Rae Sustala
NPI 1174575658
$7,488.42
in general payments reported to CMS, 2019-2025
55 companies · $1,889 in 2025
The $1,889 reported for 2025 was more than what 94% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,347 · 2022: $987 · 2023: $2,123 · 2024: $1,142 · 2025: $1,889.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,960 · Education: $194.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,960.30 |
| Education | $193.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,569.70 | 2021-2025 | |
| Glaxosmithkline, LLC. | $545.08 | 2021-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Lilly USA, LLC | $535.31 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $474.15 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $403.49 | 2021-2025 | Jardiance |
| Corium, LLC | $364.20 | 2023-2025 | Azstarys |
| Astellas Pharma US INC | $264.16 | 2023-2025 | Veozah, Myrbetriq |
| Inspire Medical Systems, INC. | $228.55 | 2025 | Inspire |
| Astrazeneca Pharmaceuticals LP | $202.67 | 2021-2024 | Airsupra |
| Corcept Therapeutics | $195.52 | 2024-2025 | Korlym |
| Axsome Therapeutics, INC. | $167.51 | 2023-2025 | Auvelity, Sunosi, Symbravo |
| Pfizer INC. | $156.05 | 2023-2025 | |
| Dexcom, INC. | $150.72 | 2022-2025 | Dexcom G6 Transmitter |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $142.03 | 2025 | Caplyta |
| Biohaven Pharmaceutical Holding Company LTD. | $118.11 | 2022 |
Show all 55 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robin Sustala listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.